» Articles » PMID: 36846105

Macular Telangiectasia Type 2: A Classification System Using MultiModal Imaging MacTel Project Report Number 10

Abstract

Purpose: To develop a severity classification for macular telangiectasia type 2 (MacTel) disease using multimodal imaging.

Design: An algorithm was used on data from a prospective natural history study of MacTel for classification development.

Subjects: A total of 1733 participants enrolled in an international natural history study of MacTel.

Methods: The Classification and Regression Trees (CART), a predictive nonparametric algorithm used in machine learning, analyzed the features of the multimodal imaging important for the development of a classification, including reading center gradings of the following digital images: stereoscopic color and red-free fundus photographs, fluorescein angiographic images, fundus autofluorescence images, and spectral-domain (SD)-OCT images. Regression models that used least square method created a decision tree using features of the ocular images into different categories of disease severity.

Main Outcome Measures: The primary target of interest for the algorithm development by CART was the change in best-corrected visual acuity (BCVA) at baseline for the right and left eyes. These analyses using the algorithm were repeated for the BCVA obtained at the last study visit of the natural history study for the right and left eyes.

Results: The CART analyses demonstrated 3 important features from the multimodal imaging for the classification: OCT hyper-reflectivity, pigment, and ellipsoid zone loss. By combining these 3 features (as absent, present, noncentral involvement, and central involvement of the macula), a 7-step scale was created, ranging from excellent to poor visual acuity. At grade 0, 3 features are not present. At the most severe grade, pigment and exudative neovascularization are present. To further validate the classification, using the Generalized Estimating Equation regression models, analyses for the annual relative risk of progression over a period of 5 years for vision loss and for progression along the scale were performed.

Conclusions: This analysis using the data from current imaging modalities in participants followed in the MacTel natural history study informed a classification for MacTel disease severity featuring variables from SD-OCT. This classification is designed to provide better communications to other clinicians, researchers, and patients.

Financial Disclosures: Proprietary or commercial disclosure may be found after the references.

Citing Articles

Genetic Background of Macular Telangiectasia Type 2.

Kuncic A, Urbancic M, Dobovsek Divjak D, Hudler P, Debeljak N Int J Mol Sci. 2025; 26(2).

PMID: 39859398 PMC: 11765629. DOI: 10.3390/ijms26020684.


Discriminative, generative artificial intelligence, and foundation models in retina imaging.

Ruamviboonsuk P, Arjkongharn N, Vongsa N, Pakaymaskul P, Kaothanthong N Taiwan J Ophthalmol. 2025; 14(4):473-485.

PMID: 39803410 PMC: 11717344. DOI: 10.4103/tjo.TJO-D-24-00064.


Prognostic Relevance of Relative Ellipsoid Zone Reflectivity for Ellipsoid Zone Loss in Macular Telangiectasia Type 2.

Goerdt L, Rodriguez Garcia J, Kunzel S, Pfau K, Raming K, Tzaridis S Invest Ophthalmol Vis Sci. 2024; 65(14):36.

PMID: 39723684 PMC: 11681918. DOI: 10.1167/iovs.65.14.36.


Multilayer Retinal Correspondence of the Structural and Vascular Anomalies in Eyes With Early Macular Telangiectasia Type 2.

Krivosic V, Dobbels Z, Duliere C, Zureik A, Tadayoni R, Gaudric A Invest Ophthalmol Vis Sci. 2024; 65(11):24.

PMID: 39283616 PMC: 11407475. DOI: 10.1167/iovs.65.11.24.


Skeleton density and ellipsoid zone loss are prognostic for progression in Macular Telangiectasia Type 2.

Goerdt L, Berger M, Jungblut J, Rodriguez Garcia J, Pfau K, Herrmann P Sci Rep. 2024; 14(1):17328.

PMID: 39068228 PMC: 11283486. DOI: 10.1038/s41598-024-67801-4.


References
1.
Sauer L, Vitale A, Andersen K, Hart B, Bernstein P . FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY (FLIO) PATTERNS IN CLINICALLY UNAFFECTED CHILDREN OF MACULAR TELANGIECTASIA TYPE 2 (MACTEL) PATIENTS. Retina. 2019; 40(4):695-704. PMC: 7062574. DOI: 10.1097/IAE.0000000000002646. View

2.
Sauer L, Vitale A, Modersitzki N, Bernstein P . LONGITUDINAL FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY ANALYSIS IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2 (MacTel). Retina. 2021; 41(7):1416-1427. DOI: 10.1097/IAE.0000000000003055. View

3.
Peto T, Heeren T, Clemons T, Sallo F, Leung I, Chew E . CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 6-The MacTel Research Group. Retina. 2017; 38 Suppl 1:S8-S13. PMC: 8326288. DOI: 10.1097/IAE.0000000000001697. View

4.
Heeren T, Chew E, Clemons T, Fruttiger M, Balaskas K, Schwartz R . Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8. Ophthalmology. 2020; 127(11):1539-1548. PMC: 8380038. DOI: 10.1016/j.ophtha.2020.03.040. View

5.
Sallo F, Leung I, Zeimer M, Clemons T, Dubis A, Fruttiger M . ABNORMAL RETINAL REFLECTIVITY TO SHORT-WAVELENGTH LIGHT IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA. Retina. 2017; 38 Suppl 1:S79-S88. PMC: 5726908. DOI: 10.1097/IAE.0000000000001728. View